-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $47

Benzinga·10/30/2025 11:16:02
Listen to the news
Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $46 to $47.